Journal
NATURE REVIEWS NEPHROLOGY
Volume 6, Issue 3, Pages 179-183Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneph.2009.229
Keywords
-
Categories
Funding
- Merit review program of the veterans Administration, Washington, DC
- NIH
- American Heart Association
- National Kidney Foundation
- Western Institute for Biomedical research
- Allocure, Inc
Ask authors/readers for more resources
Acute kidney injury (AKI) is a common clinical complication, associated with poor outcomes and the development of chronic kidney disease. Despite major advances in the understanding of its pathophysiology, available therapies for AKI are only supportive; therefore, adequate functional recovery from AKI must predominantly rely on the kidney's own reparative ability. An extensive body of preclinical data from our own and from other laboratories has shown that administration of adult multipotent marrow stromal cells ( commonly referred to as mesenchymal stem cells [MSCs]), effectively ameliorates experimental AKI by exerting paracrine renoprotective effects and by stimulating tissue repair. Based on these findings, a clinical trial has been conducted to investigate the safety and efficacy of MSCs administered to open-heart surgery patients who are at high risk of postoperative AKI. In this Perspectives article, we discuss some of the early data from this trial and describe potential applications for stem cell therapies in other fields of nephrology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available